Your shopping cart is currently empty

Angiogenin Fragment (108-123) acetate is the C-terminal fragment 108-123 of angiogenin, inhibiting both its enzymatic and biological activities.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $195 | - | In Stock | |
| 5 mg | $483 | - | In Stock | |
| 10 mg | $691 | - | In Stock | |
| 25 mg | $1,080 | - | In Stock | |
| 50 mg | $1,490 | - | In Stock |
| Description | Angiogenin Fragment (108-123) acetate is the C-terminal fragment 108-123 of angiogenin, inhibiting both its enzymatic and biological activities. |
| In vitro | Angiogenin Fragment (108-123) acetate can inhibit the initial degradation rate of tRNA catalyzed by angiogenin in a concentration-dependent manner, with a Ki value of 278 μM. When tRNA is used as the reaction substrate, Angiogenin Fragment (108-123) acetate can also suppress the nuclease activity of angiogenin. Furthermore, in the chick chorioallantoic membrane assay, Angiogenin Fragment (108-123) acetate significantly attenuates angiogenin-induced neovascularization [1]. |
| Synonyms | Angiogenin Fragment (108-123) acetate(112173-48-5 Free base) |
| Sequence | Glu-Asn-Gly-Leu-Pro-Val-His-Leu-Asp-Gln-Ser-Ile-Phe-Arg-Arg-Pro |
| Sequence Short | ENGLPVHLDQSIFRRP |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.